Halozyme To Report Second Quarter 2023 Financial and Operating Results

Rhea-AI Summary

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, with a conference call to discuss the results. The live webcast and replay of the conference call will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.

SAN DIEGO, July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading.

Halozyme will host a conference call on Tuesday, August 8, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/attendee/874394866.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in six commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO® and NOCDURNA® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Dawn Schottlandt
Argot Partners
212-600-1902
Halozyme@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2023-financial-and-operating-results-301884812.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

What is the release date of Halozyme's second quarter 2023 financial and operating results?

The release date is Tuesday, August 8, 2023.

When is the conference call to discuss the results taking place?

The conference call will be on Tuesday, August 8, 2023 at 4:30 p.m. ET/1:30 p.m. PT.

How can I access the conference call live?

The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/attendee/874394866.

Where can I find the live webcast and replay of the conference call?

The live webcast and replay will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.